Jazz Pharmaceuticals Plc (JAZZ) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Incyte Corp.

Neurocrine Biosciences, Inc.

Repligen Corp.

United Therapeutics Corp.

Alnylam Pharmaceuticals, Inc.

Jazz Pharmaceuticals Plc

Sarepta Therapeutics, Inc.

Royalty Pharma Plc

Walgreens Boots Alliance, Inc.

Viatris, Inc.

Roivant Sciences Ltd.

Why is Jazz Pharmaceuticals Plc ?

Poor Management Efficiency with a low ROCE of 9.96%

The company has been able to generate a Return on Capital Employed (avg) of 9.96% signifying low profitability per unit of total capital (equity and debt)

Healthy long term growth as Net Sales has grown by an annual rate of 12.77%

The company declared negative results in Mar'25 after positive results in Dec'24

ROCE(HY) Lowest at -9.06%
DEBTORS TURNOVER RATIO(HY) Lowest at 5.59 times
PRE-TAX PROFIT(Q) Fallen at -35.7%

Risky -

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of 39.80%, its profits have risen by 24.9% ; the PEG ratio of the company is 0.6

High Institutional Holdings at 100%

These investors have better capability and resources to analyse fundamentals of companies than most retail investors.

Market Beating Performance

The stock has generated a return of 39.80% in the last 1 year, much higher than market (S&P 500) returns of 13.68%

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Jazz Pharmaceuticals Plc should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Jazz Pharmaceuticals Plc for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Jazz Pharmaceuticals Plc

39.8%

1.77

41.57%

S&P 500

13.5%

0.71

19.28%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

12.77%

EBIT Growth (5y)

-3.55%

EBIT to Interest (avg)

2.75

Debt to EBITDA (avg)

2.97

Net Debt to Equity (avg)

0.67

Sales to Capital Employed (avg)

0.41

Tax Ratio

Tax Ratio is Negative%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

100.00%

ROCE (avg)

9.96%

ROE (avg)

10.20%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

2.83

EV to EBIT

28.20

EV to EBITDA

12.10

EV to Capital Employed

1.99

EV to Sales

3.50

PEG Ratio

0.64

Dividend Yield

ROCE (Latest)

7.07%

ROE (Latest)

16.43%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Bullish

RSI

No Signal

Bollinger Bands

Bullish

Mildly Bullish

Moving Averages

Bullish (Daily)

KST

Mildly Bearish

Bullish

Dow Theory

Mildly Bearish

No Trend

OBV

Mildly Bearish

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD 1,391.84 MM

RAW MATERIAL COST(Y)

Fallen by 1.22% (YoY

INVENTORY TURNOVER RATIO(HY)

Highest at 2.2 times

NET SALES(Q)

Highest at USD 1,126.11 MM

NET PROFIT(Q)

Highest at USD 362.23 MM

EPS(Q)

Highest at USD 4.08

-4What is not working for the Company

ROCE(HY)

Lowest at -9.06%

DEBTORS TURNOVER RATIO(HY)

Lowest at 5.59 times

PRE-TAX PROFIT(Q)

Fallen at -35.7%

Here's what is working for Jazz Pharmaceuticals Plc

Operating Cash Flow

Highest at USD 1,391.84 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Sales

Highest at USD 1,126.11 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (USD MM)

Net Profit

Highest at USD 362.23 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

Net Profit

At USD 362.23 MM has Grown at 80.52%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is positive

Net Profit (USD MM)

EPS

Highest at USD 4.08

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Inventory Turnover Ratio

Highest at 2.2 times

in the last five Semi-Annual periods

MOJO Watch

Company has been able to sell its inventory faster

Inventory Turnover Ratio

Raw Material Cost

Fallen by 1.22% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at USD 178.25 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (USD MM)

Here's what is not working for Jazz Pharmaceuticals Plc

Pre-Tax Profit

Fallen at -35.7%

Year on Year (YoY)

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (USD MM)

Debtors Turnover Ratio

Lowest at 5.59 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Non Operating Income

Highest at USD 2.78 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income